UnitedHealth Group stock falls as investors weigh 2025 results

UnitedHealth Group (US91324P1021) stock reflects a company that posted 2025 revenue of $400.3 billion and adjusted earnings per share of $27.66, while guiding to 2026 revenue of $445.5 billion to $448.0 billion. The latest investor relations material on UnitedHealth Group investors frames the business around a large health services and benefits base, with scale still the central story for the shares.

Revenue up 11.1%

Revenue rose 11.1% from $360.8 billion in 2024 to $400.3 billion in 2025, a jump of $39.5 billion that sets the baseline for 2026 expectations. Adjusted EPS increased from $24.92 in 2024 to $27.66 in 2025, which gives investors a second hard number to compare against the new outlook.

That comparison matters because the 2026 revenue guide of $445.5 billion to $448.0 billion implies another step up in scale. The midpoint, $446.75 billion, sits $46.45 billion above 2025 revenue and suggests management is still planning for expansion rather than stability.

Margins and guidance

UnitedHealth Group's 2025 operating structure also matters because revenue alone does not explain equity value. The company reported 2025 adjusted EPS of $27.66, and the 2026 revenue guide came alongside a business that remains anchored by insurance and services operations.

For investors, the more useful comparison is between the 2025 earnings base and the 2026 sales target. A revenue guide up 11.6% at the midpoint versus 2025 provides a concrete benchmark for future margin execution.

Read deeper

UnitedHealth Group's investor materials remain the most direct source for the 2025 and 2026 numbers used here. The same page also helps place the stock inside the company's broader earnings and capital allocation framework.

Products and services

UnitedHealth Group's core businesses are UnitedHealthcare and Optum, the two names that carry most of the company's operating weight. In practice, the stock is driven less by any single product than by the interaction between membership, care delivery, and services scale.

That mix explains why revenue growth and EPS growth both matter in the same article. A 2025 revenue base of $400.3 billion and adjusted EPS of $27.66 are not abstract figures; they are the operating reference point for the 2026 plan.

Stock level and market context

UnitedHealth Group stock should be read against those annual figures rather than against a slogan. The market value logic is straightforward: a company that lifted revenue by $39.5 billion year on year and guided to another $45.2 billion to $47.7 billion of revenue growth in 2026 is still being judged on execution, not on a one-off quarter.

As of 18 July 2026, the article uses the latest available investor-relations figures as the market context for the shares. The stock closes this note with the 2025 revenue of $400.3 billion, adjusted EPS of $27.66, and 2026 revenue guidance of $445.5 billion to $448.0 billion as the numbers that matter most.